Growth Metrics

Novartis Ag (NVS) Capital Expenditures (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 43.19%
Dec 31, 2025 -72.03%
Sep 30, 2025 -6.95%
Jun 30, 2025 -30.31%
Mar 31, 2025 54.48%
Dec 31, 2024 -73.83%
Sep 30, 2024 -23.46%
Jun 30, 2024 -14.54%
Mar 31, 2024 44.09%
Dec 31, 2023 -55.56%
Sep 30, 2023 -16.00%
Jun 30, 2023 -33.93%
Mar 31, 2023 45.10%
Dec 31, 2022 -38.46%
Sep 30, 2022 14.01%
Jun 30, 2022 0.00%
Mar 31, 2022 44.13%
Dec 31, 2021 -31.05%
Sep 30, 2021 -9.35%
Jun 30, 2021 -30.49%
Mar 31, 2021 52.78%
Dec 31, 2020 -86.74%
Sep 30, 2020 -17.23%
Jun 30, 2020 -0.42%
Mar 31, 2020 48.59%
Dec 31, 2019 -29.13%
Sep 30, 2019 -27.96%
Jun 30, 2019 1.06%
Mar 31, 2019 36.49%
Dec 31, 2018 -50.51%
Sep 30, 2018 -14.79%
Jun 30, 2018 0.39%
Mar 31, 2018 59.56%
Dec 31, 2017 -67.02%
Sep 30, 2017 -15.06%
Jun 30, 2017 3.49%
Mar 31, 2017 41.30%
Dec 31, 2016 -32.28%
Sep 30, 2016 1.12%
Jun 30, 2016 -16.36%
Mar 31, 2016 48.87%
Dec 31, 2015 -30.05%
Sep 30, 2015 -102,296,719.79%
Jun 30, 2015 -20.68%
Mar 31, 2015 43.49%
Dec 31, 2014 -24.25%
Sep 30, 2014 -3.73%
Jun 30, 2014 -33.61%
Sep 30, 2013 -19.91%
Jun 30, 2013 -27.36%
Sep 30, 2012 -9.60%
Jun 30, 2012 -46.60%
Mar 31, 2012 47.52%
Dec 31, 2011 -53.92%
Sep 30, 2011 -12.58%
Jun 30, 2011 -8.11%
Mar 31, 2011 37.74%
Dec 31, 2010 -94.51%
Sep 30, 2010 2.54%
Jun 30, 2010 -16.78%
Mar 31, 2010 50.89%
Dec 31, 2009 -49.16%
Sep 30, 2009 14.43%
Jun 30, 2009 -31.79%